Cannabis shows potential for treating insomnia
Over an 18-month period, patients suffering with insomnia who were treated with cannabis- based medical products reported improvement in sleep. The findings were published on Aug. 27, 2025… read more.
Over an 18-month period, patients suffering with insomnia who were treated with cannabis- based medical products reported improvement in sleep. The findings were published on Aug. 27, 2025… read more.
Biogen Inc and Stoke Therapeutics Inc, a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, announced presentations of new clinical data… read more.
Alkermes announced plans to present detailed results from its Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 (NT1) at World Sleep Congress, taking place… read more.
Alzheimer’s disease (AD) is the most common neurodegenerative disease in older people, affecting up to 1 in 20 individuals aged 65 and above. In addition to environmental and… read more.
The study examined over a thousand women aged 18 to 49. Of these, 358 had suffered an ischemic stroke. Researchers compared the pregnancy histories of these women with… read more.
Despite evidence of the risk of malformations at birth, or birth defects, use of some antiseizure drugs during pregnancy has persisted, according to a study published on July… read more.
Roche announced that new data from its Alzheimer’s development portfolio is being presented at the Alzheimer’s Association International Conference (AAIC) in Toronto, Canada (July 27-30). These data exemplify… read more.
Researchers report that treatment of type 2 diabetes with glucagon- like peptide- 1 receptor agonists (GLP- 1 RAs) more effectively reduces the subsequent risk of dementia than treatment… read more.
Eisai Co., Ltd. announced that the company will present the latest findings from its robust Alzheimer’s disease (AD) pipeline and research, including our dual-acting, anti-amyloid beta (Aβ) protofibril… read more.
Eisai Co., Ltd. and Biogen Inc. announced that the European Commission (EC) has granted the amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) Marketing Authorization (MA) in the European Union… read more.
Biogen Inc. anounced upcoming scientific presentations at the 2025 Alzheimer’s Association International Conference (AAIC), taking place July 27-31 in Toronto, Canada. Data on LEQEMB® (lecanemab) will include 48-month results… read more.
A new study that examined older and newer medications to treat seizures has found that using some medications during pregnancy is linked to an increased risk of malformations… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.